Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 41.49 -2.63% -1.12
ACAD closed down 2.63 percent on Monday, October 19, 2020, on 65 percent of normal volume.
Earnings due: Oct 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical ACAD trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
200 DMA Resistance Bearish -2.63%
Shooting Star Candlestick Bearish -2.63%
Lizard Bearish Bearish Day Trade Setup -2.63%
Bollinger Band Squeeze Range Contraction -2.63%
Older End-of-Day Gignals for ACAD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 5 hours ago
Fell Below 20 DMA about 5 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Down 1% about 10 hours ago
Up 1% about 10 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Biopharmaceutical Health Pharmaceutical Industry Chemical Compounds Medication Alzheimer's Disease Parkinson's Disease Schizophrenia Neurological Disorders Glaucoma Chronic Pain Treatment Of Parkinson's Disease Treatment Of Alzheimer's Disease Treatment Of Glaucoma Muscarinic Agonist

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 58.72
52 Week Low 30.02
Average Volume 1,151,985
200-Day Moving Average 44.07
50-Day Moving Average 40.09
20-Day Moving Average 41.72
10-Day Moving Average 42.66
Average True Range 1.38
ADX 13.75
+DI 21.33
-DI 21.26
Chandelier Exit (Long, 3 ATRs ) 40.15
Chandelier Exit (Short, 3 ATRs ) 41.69
Upper Bollinger Band 44.21
Lower Bollinger Band 39.23
Percent B (%b) 0.45
BandWidth 11.93
MACD Line 0.64
MACD Signal Line 0.66
MACD Histogram -0.0217
Fundamentals Value
Market Cap 6.59 Billion
Num Shares 159 Million
EPS -1.97
Price-to-Earnings (P/E) Ratio -21.10
Price-to-Sales 16.64
Price-to-Book 10.24
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.60
Resistance 3 (R3) 44.92 44.20 44.08
Resistance 2 (R2) 44.20 43.40 44.04 43.91
Resistance 1 (R1) 42.84 42.91 42.48 42.53 43.74
Pivot Point 42.12 42.12 41.94 41.96 42.12
Support 1 (S1) 40.77 41.33 40.41 40.45 39.24
Support 2 (S2) 40.05 40.84 39.89 39.07
Support 3 (S3) 38.69 40.05 38.90
Support 4 (S4) 38.38